The role of the small GTPase Rab31 in cancer

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 1, 2015, Pages 1-10

  Chua, Christelle En Lin ^a,b   Tang, Bor Luen ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer; Membrane traffic; Mucin1; Rab31

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RAB PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; BIOLOGICAL MODEL; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RAB GTP-BINDING PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84921599178     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12403     Document Type: Article

References (132)

1. Mizuno-Yamasaki E, Rivera-Molina F, Novick P. GTPase networks in membrane traffic. Annu Rev Biochem. 2012; 81: 637-59.
2. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009; 10: 513-25.
3. Kelly EE, Horgan CP, Goud B, et al. The Rab family of proteins: 25 years on. Biochem Soc Trans. 2012; 40: 1337-47.
4. Rojas AM, Fuentes G, Rausell A, et al. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J Cell Biol. 2012; 196: 189-201.
5. Seabra MC, Wasmeier C. Controlling the location and activation of Rab GTPases. Curr Opin Cell Biol. 2004; 16: 451-7.
6. Pfeffer S, Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol. 2004; 5: 886-96.
7. Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011; 91: 119-49.
8. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008; 9: 517-31.
9. Itzen A, Goody RS. GTPases involved in vesicular trafficking: structures and mechanisms. Semin Cell Dev Biol. 2011; 22: 48-56.
10. Pfeffer SR, Dirac-Svejstrup AB, Soldati T. Rab GDP dissociation inhibitor: putting rab GTPases in the right place. J Biol Chem. 1995; 270: 17057-9.
11. Shen F, Seabra MC. Mechanism of digeranylgeranylation of Rab proteins. Formation of a complex between monogeranylgeranyl-Rab and Rab escort protein. J Biol Chem. 1996; 271: 3692-8.
12. Gomes AQ, Ali BR, Ramalho JS, et al. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell. 2003; 14: 1882-99.
13. Ali BR, Seabra MC. Targeting of Rab GTPases to cellular membranes. Biochem Soc Trans. 2005; 33: 652-6.
14. Barr F, Lambright DG. Rab GEFs and GAPs. Curr Opin Cell Biol. 2010; 22: 461-70.
15. Blümer J, Rey J, Dehmelt L, et al. RabGEFs are a major determinant for specific Rab membrane targeting. J Cell Biol. 2013; 200: 287-300.
16. Barrowman J, Bhandari D, Reinisch K, et al. TRAPP complexes in membrane traffic: convergence through a common Rab. Nat Rev Mol Cell Biol. 2010; 11: 759-63.
17. Horgan CP, McCaffrey MW. Rab GTPases and microtubule motors. Biochem Soc Trans. 2011; 39: 1202-6.
18. Novick P, Medkova M, Dong G, et al. Interactions between Rabs, tethers, SNAREs and their regulators in exocytosis. Biochem Soc Trans. 2006; 34: 683-6.
19. Aloisi AL, Bucci C. Rab GTPases-cargo direct interactions: fine modulators of intracellular trafficking. Histol Histopathol. 2013; 28: 839-49.
20. Fukuda M. TBC proteins: GAPs for mammalian small GTPase Rab? Biosci Rep. 2011; 31: 159-68.
21. Verhoeven K, De Jonghe P, Coen K, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet. 2003; 72: 722-7.
22. Spinosa MR, Progida C, De Luca A, et al. Functional characterization of Rab7 mutant proteins associated with Charcot-Marie-Tooth type 2B disease. J Neurosci. 2008; 28: 1640-8.
23. Bem D, Yoshimura SI, Nunes-Bastos R, et al. Loss-of-function mutations in RAB18 cause Warburg micro syndrome. Am J Hum Genet. 2011; 88: 499-507.
24. Liegel RP, Handley MT, Ronchetti A, et al. Loss-of-function mutations in TBC1D20 cause cataracts and male infertility in blind sterile mice and Warburg micro syndrome in humans. Am J Hum Genet. 2013; 93: 1001-14.
25. Jenkins D, Seelow D, Jehee FS, et al. RAB23 mutations in Carpenter syndrome imply an unexpected role for hedgehog signaling in cranial-suture development and obesity. Am J Hum Genet. 2007; 80: 1162-70.
26. Jenkins D, Baynam G, De Catte L, et al. Carpenter syndrome: extended RAB23 mutation spectrum and analysis of nonsense-mediated mRNA decay. Hum Mutat. 2011; 32: E2069-78.
27. Barral DC, Ramalho JS, Anders R, et al. Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J Clin Invest. 2002; 110: 247-57.
28. Giannandrea M, Bianchi V, Mignogna ML, et al. Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. Am J Hum Genet. 2010; 86: 185-95.
29. Oiso N, Riddle SR, Serikawa T, et al. The rat Ruby (R) locus is Rab38: identical mutations in Fawn-hooded and Tester-Moriyama rats derived from an ancestral Long Evans rat sub-strain. Mamm Genome. 2004; 15: 307-14.
30. Gerondopoulos A, Langemeyer L, Liang JR, et al. BLOC-3 mutated in Hermansky-Pudlak syndrome is a Rab32/38 guanine nucleotide exchange factor. Curr Biol. 2012; 22: 2135-9.
31. Cogli L, Piro F, Bucci C. Rab7 and the CMT2B disease. Biochem Soc Trans. 2009; 37: 1027-31.
32. Chua CEL, Tang BL. Rabs, SNAREs and α-synuclein-membrane trafficking defects in synucleinopathies. Brain Res Rev. 2011; 67: 268-81.
33. D'Adamo P, Masetti M, Bianchi V, et al. RAB GTPases and RAB-interacting proteins and their role in the control of cognitive functions. Neurosci Biobehav Rev. 2014; pii: S0149-7634(14)00003-7.
34. Krzewski K, Cullinane AR. Evidence for defective Rab GTPase-dependent cargo traffic in immune disorders. Exp Cell Res. 2013; 319: 2360-7.
35. Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta. 2009; 1795: 110-6.
36. Recchi C, Seabra MC. Novel functions for Rab GTPases in multiple aspects of tumour progression. Biochem Soc Trans. 2012; 40: 1398-403.
37. Shimada K, Uzawa K, Kato M, et al. Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 2005; 92: 1915-21.
38. Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18: 883-91.
39. Culine S, Honoré N, Tavitian A, et al. Overexpression of the ras-related rab2 gene product in peripheral blood mononuclear cells from patients with hematological and solid neoplasms. Cancer Res. 1992; 52: 3083-8.
40. Culine S, Honore N, Closson V, et al. A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours. Eur J Cancer. 1994; 30A: 670-4.
41. Torres VA, Stupack DG. Rab5 in the regulation of cell motility and invasion. Curr Protein Pept Sci. 2011; 12: 43-51.
42. Mendoza P, Ortiz R, Díaz J, et al. Rab5 activation promotes focal adhesion disassembly, migration and invasiveness in tumor cells. J Cell Sci. 2013; 126: 3835-47.
43. Yu L, Hui-chen F, Chen Y, et al. Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential. Clin Exp Metastasis. 1999; 17: 213-9.
44. Croizet-Berger K, Daumerie C, Couvreur M, et al. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci USA. 2002; 99: 8277-82.
45. Fukui K, Tamura S, Wada A, et al. Expression of Rab5a in hepatocellular carcinoma: possible involvement in epidermal growth factor signaling. Hepatol Res. 2007; 37: 957-65.
46. Zhao Z, Liu XF, Wu HC, et al. Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway. Cancer Sci. 2010; 101: 1454-62.
47. Onodera Y, Nam JM, Hashimoto A, et al. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion. J Cell Biol. 2012; 197: 983-96.
48. Steffan JJ, Dykes SS, Coleman DT, et al. Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS ONE. 2014; 9: e87882.
49. Amillet JM, Ferbus D, Real FX, et al. Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Hum Pathol. 2006; 37: 256-63.
50. Hackenbeck T, Huber R, Schietke R, et al. The GTPase RAB20 is a HIF target with mitochondrial localization mediating apoptosis in hypoxia. Biochim Biophys Acta. 2011; 1813: 1-3.
51. Liu YJ, Wang Q, Li W, et al. Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenterol. 2007; 13: 1010-7.
52. Hou Q, Wu YH, Grabsch H, et al. Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res. 2008; 68: 4623-30.
53. Hendrix A, Braems G, Bracke M, et al. The secretory small GTPase Rab27B as a marker for breast cancer progression. Oncotarget. 2010; 1: 304-8.
54. Hendrix A, Maynard D, Pauwels P, et al. Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst. 2010; 102: 866-80.
55. Zhang JX, Huang XX, Cai MB, et al. Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis. J Transl Med. 2012; 10: 242.
56. Kelly EE, Horgan CP, McCaffrey MW. Rab11 proteins in health and disease. Biochem Soc Trans. 2012; 40: 1360-7.
57. Goldenring JR, Shen KR, Vaughan HD, et al. Identification of a small GTP-binding protein, Rab25, expressed in the gastrointestinal mucosa, kidney, and lung. J Biol Chem. 1993; 268: 18419-22.
58. Casanova JE, Wang X, Kumar R, et al. Association of Rab25 and Rab11a with the apical recycling system of polarized Madin-Darby canine kidney cells. Mol Biol Cell. 1999; 10: 47-61.
59. Cheng KW, Lahad JP, Kuo WL, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004; 10: 1251-6.
60. Cheng JM, Volk L, Janaki DKM, et al. Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer. 2010; 126: 2799-812.
61. Tong M, Chan KW, Bao JYJ, et al. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res. 2012; 72: 6024-35.
62. Zhang J, Wei J, Lu J, et al. Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3β/Snail signaling. Carcinogenesis. 2013; 34: 2401-8.
63. Amornphimoltham P, Rechache K, Thompson J, et al. Rab25 regulates invasion and metastasis in head and neck cancer. Clin Cancer Res. 2013; 19: 1375-88.
64. Zhang J, Liu X, Datta A, et al. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009; 119: 2171-83.
65. Tang BL. Is Rab25 a tumor promoter or suppressor-context dependency on RCP status? Tumour Biol. 2010; 31: 359-61.
66. Hofsli E, Wheeler TE, Langaas M, et al. Identification of novel neuroendocrine-specific tumour genes. Br J Cancer. 2008; 99: 1330-9.
67. Zhou J, Fogelgren B, Wang Z, et al. Isolation of genes from the rhabdoid tumor deletion region in chromosome band 22q11.2. Gene. 2000; 241: 133-41.
68. Wu CY, Tseng RC, Hsu HS, et al. Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer. Lung Cancer. 2009; 63: 360-7.
69. Zhai H, Song B, Xu X, et al. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013; 32: 1570-9.
70. Zoppino FCM, Militello RD, Slavin I, et al. Autophagosome formation depends on the small GTPase Rab1 and functional ER exit sites. Traffic. 2010; 11: 1246-61.
71. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30: 2644-58.
72. Tanaka T, Arai M, Wu S, et al. Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer. Oncol Rep. 2011; 26: 1329-35.
73. Ye F, Tang H, Liu Q, et al. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014; 12: 17.
74. Liu Q, Tang H, Liu X, et al. miR-200b as a prognostic factor targets multiple members of RAB family in glioma. Med Oncol. 2014; 31: 859.
75. Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013; 5: a016949.
76. Bravo-Cordero JJ, Marrero-Diaz R, Megías D, et al. MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J. 2007; 26: 1499-510.
77. Caswell PT, Spence HJ, Parsons M, et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell. 2007; 13: 496-510.
78. Caswell PT, Chan M, Lindsay AJ, et al. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol. 2008; 183: 143-55.
79. Dozynkiewicz MA, Jamieson NB, Macpherson I, et al. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell. 2012; 22: 131-45.
80. Chen D, Guo J, Miki T, et al. Molecular cloning of two novel rab genes from human melanocytes. Gene. 1996; 174: 129-34.
81. Bao X, Faris AE, Jang EK, et al. Molecular cloning, bacterial expression and properties of Rab31 and Rab32. Eur J Biochem. 2002; 269: 259-71.
82. Rodriguez-Gabin AG, Cammer M, Almazan G, et al. Role of rRAB22b, an oligodendrocyte protein, in regulation of transport of vesicles from trans Golgi to endocytic compartments. J Neurosci Res. 2001; 66: 1149-60.
83. Ng EL, Wang Y, Tang BL. Rab22B's role in trans-Golgi network membrane dynamics. Biochem Biophys Res Commun. 2007; 361: 751-7.
84. Diekmann Y, Seixas E, Gouw M, et al. Thousands of rab GTPases for the cell biologist. PLoS Comput Biol. 2011; 7: e1002217.
85. Klöpper TH, Kienle N, Fasshauer D, et al. Untangling the evolution of Rab G proteins: implications of a comprehensive genomic analysis. BMC Biol. 2012; 10: 71.
86. Rodriguez-Gabin AG, Yin X, Si Q, et al. Transport of mannose-6-phosphate receptors from the trans-Golgi network to endosomes requires Rab31. Exp Cell Res. 2009; 315: 2215-30.
87. Rodriguez-Gabin AG, Ortiz E, Demoliner K, et al. Interaction of Rab31 and OCRL-1 in oligodendrocytes: its role in transport of mannose 6-phosphate receptors. J Neurosci Res. 2010; 88: 589-604.
88. Ng EL, Ng JJ, Liang F, et al. Rab22B is expressed in the CNS astroglia lineage and plays a role in epidermal growth factor receptor trafficking in A431 cells. J Cell Physiol. 2009; 221: 716-28.
89. King GJ, Stöckli J, Hu SH, et al. Membrane curvature protein exhibits interdomain flexibility and binds a small GTPase. J Biol Chem. 2012; 287: 40996-1006.
90. Lodhi IJ, Chiang SH, Chang L, et al. Gapex-5, a Rab31 guanine nucleotide exchange factor that regulates Glut4 trafficking in adipocytes. Cell Metab. 2007; 5: 59-72.
91. Kajiho H, Sakurai K, Minoda T, et al. Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J Biol Chem. 2011; 286: 24364-73.
92. Abba MC, Hu Y, Sun H, et al. Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genom. 2005; 6: 37.
93. Luther T, Kotzsch M, Meye A, et al. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost. 2003; 89: 705-17.
94. Kotzsch M, Farthmann J, Meye A, et al. Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer. 2005; 41: 2760-8.
95. Sato S, Kopitz C, Grismayer B, et al. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat. 2011; 127: 649-57.
96. Kotzsch M, Sieuwerts AM, Grosser M, et al. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat. 2008; 111: 229-40.
97. Kotzsch M, Dorn J, Doetzer K, et al. mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer. Biol Chem. 2011; 392: 1047-51.
98. Yim EK, Tong SY, Ho EM, et al. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep. 2009; 21: 549-57.
99. Serão NVL, Delfino KR, Southey BR, et al. Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genom. 2011; 4: 49.
100. Kunkle BW, Yoo C, Roy D. Reverse engineering of modified genes by bayesian network analysis defines molecular determinants critical to the development of glioblastoma. PLoS ONE. 2013; 8: e64140.
101. Heinonen M, Hemmes A, Salmenkivi K, et al. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol. 2011; 224: 529-39.
102. Simone LE, Keene JD. Mechanisms coordinating ELAV/Hu mRNA regulons. Curr Opin Genet Dev. 2013; 23: 35-43.
103. Heinonen M, Bono P, Narko K, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005; 65: 2157-61.
104. Heinonen M, Fagerholm R, Aaltonen K, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007; 13: 6959-63.
105. Jin C, Rajabi H, Pitroda S, et al. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS ONE. 2012; 7: e39432.
106. Rakha EA, Boyce RWG, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18: 1295-304.
107. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32: 1073-81.
108. Kinlough CL, Poland PA, Bruns JB, et al. MUC1 membrane trafficking is modulated by multiple interactions. J Biol Chem. 2004; 279: 53071-7.
109. Leng Y, Cao C, Ren J, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007; 282: 19321-30.
110. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 2006; 21: 295-305.
111. Ahmad R, Rajabi H, Kosugi M, et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011; 4: ra9.
112. Grismayer B, Sölch S, Seubert B, et al. Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer. 2012; 11: 62.
113. Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003; 23: 7177-88.
114. Han B, Nakamura M, Mori I, et al. Urokinase-type plasminogen activator system and breast cancer. Oncol Rep. 2005; 14: 105-12.
115. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11: 23-36.
116. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci. 2008; 65: 1916-32.
117. Grismayer B, Sato S, Kopitz C, et al. Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes. Biol Chem. 2012; 393: 1449-55.
118. Nykjaer A, Christensen EI, Vorum H, et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 1998; 141: 815-28.
119. Kreiling JL, Byrd JC, Deisz RJ, et al. Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR. J Biol Chem. 2003; 278: 20628-37.
120. Li Y, Liu D, Chen D, et al. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003; 22: 6107-10.
121. Gnemmi V, Bouillez A, Gaudelot K, et al. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014; 346: 225-36.
122. Ahmad R, Raina D, Joshi MD, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009; 69: 7013-21.
123. Li Y, Ren J, Yu W, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem. 2001; 276: 35239-42.
124. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene. 2007; 26: 1693-701.
125. Kato K, Lillehoj EP, Park YS, et al. Membrane-tethered MUC1 mucin is phosphorylated by epidermal growth factor receptor in airway epithelial cells and associates with TLR5 to inhibit recruitment of MyD88. J Immunol. 2012; 188: 2014-22.
126. Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 2009; 34: 1691-9.
127. Chaika NV, Gebregiworgis T, Lewallen ME, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci USA. 2012; 109: 13787-92.
128. Chua CEL, Tang BL. Engagement of the small GTPase Rab31 and its effector, early endosome antigen 1, is important for trafficking of ligand-bound epidermal growth factor receptor from early to late endosome. J Biol Chem. 2014; 289: 12375-89.
129. Su X, Kong C, Stahl PD. GAPex-5 mediates ubiquitination, trafficking, and degradation of epidermal growth factor receptor. J Biol Chem. 2007; 282: 21278-84.
130. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000; 2: 176-83.
131. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28: 357-60.
132. Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013; 14: 304-14.